Autoimmune bullous dermatoses in the elderly: An update on pathophysiology, diagnosis and management

Drugs and Aging

Volumn 27, Issue 1, 2010, Pages 1-19

  Mutasim, Diya F ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune disorders, general; Elderly; Epidermolysis bullosa, general; Linear IgA bullous dermatosis, general; Pemphigoid, general; Pemphigus, general

Indexed keywords

ALLOPURINOL; AMIODARONE; ANTIFUNGAL AGENT; AZATHIOPRINE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DANAZOL; DAPSONE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; IMMUNOGLOBULIN; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; RITUXIMAB; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VERAPAMIL;

ACUTE NONLYMPHOCYTIC LEUKEMIA; AGED; AGRANULOCYTOSIS; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; AZOOSPERMIA; BEHAVIOR CHANGE; BLINDNESS; BONE MARROW SUPPRESSION; BONE NECROSIS; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; CARDIOTOXICITY; CATARACT; CHILL; CREATININE BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; EDEMA; ELDERLY CARE; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; FIBROSING ALVEOLITIS; FLUSHING; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GRAPEFRUIT JUICE; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION SENSITIVITY; INSOMNIA; INTERSTITIAL PNEUMONIA; INTESTINE ULCER; KIDNEY DISEASE; LEUKEMIA; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOMA; METHEMOGLOBINEMIA; MOOD CHANGE; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; NEUROLOGIC DISEASE; OOCYTE DEVELOPMENT; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PARANEOPLASTIC PEMPHIGUS; PATHOPHYSIOLOGY; PEMPHIGOID; PHOTOCHEMOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; RASH; REPRODUCTIVE TOXICITY; REVIEW; SCAR FORMATION; SEPSIS; SIDE EFFECT; SPERMATOGENESIS; STOMATITIS; SUICIDAL IDEATION; TACHYCARDIA; THROMBOCYTOPENIA; THYMOMA; TREMOR; ULCER; UROGENITAL TRACT DISEASE; WEAKNESS;

ADRENAL CORTEX HORMONES; AGED; AUTOIMMUNE DISEASES; AUTOIMMUNITY; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGOID, BULLOUS; SKIN DISEASES, VESICULOBULLOUS; WOUNDS AND INJURIES;

EID: 73849090894     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11318600-000000000-00000     Document Type: Review

References (140)

1. Mutasim DF. Autoimmune bullous dermatoses in the elderly: diagnosis and management. Drugs Aging 2003; 20 (9): 663-681
2. Grove GL, Duncan S, Kligman AM. Effect of aging on the blistering of human skin with ammonium hydroxide. Br J Dermatol 1982; 107: 383-400
3. Montagna W, Carlisle K. Structural changes in aging human skin. J Invest Dermatol 1979; 73: 47-53
4. Dubey DP, Yunis EJ. Aging and nutritional effects on immune functions in humans. In: Stites DP, Terr AI, editors. Basic and clinical immunology. 7th ed. Norwalk (CT): Appleton and Lange, 1991: 190-193
5. Burgeson RE, Christiano AM. The dermal-epidermal junction. Curr Opin Cell Biol 1998; 9: 651-658
6. Roscoe JT, Diaz L, Sampaio SA, et al. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 1985; 85: 538-541
7. Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-1196
8. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-877
9. Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964; 117: 505-510
10. Rappersberger K, Roos N, Stanley JR. Immunomorphological and biochemical identification of the pemphigus foliaceus autoantigen within desmosomes. J Invest Dermatol 1992; 99: 323-330
11. Karpati S, AmagaiM, Prussick R, et al. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol 1993; 122: 409-415
12. Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53: 291-325
13. Eyre RW, Stanley JR. Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. J Clin Invest 1988; 81: 807-812
14. Hu CH, Michel B, Schlitz JR. Epidermal acantholysis induced in vitro by pemphigus autoantibody. Am J Pathol 1978; 90: 345-351
15. Diaz LA, Giudice GJ. End of the century overview of skin blisters. Arch Dermatol 2000; 136: 106-112
16. Stanley JR. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest 1989; 83: 1443-1448
17. Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997; 100: 1256-1263
18. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP 180. J Clin Invest 1993; 92: 2480-2488
19. Sitaru C, Mihai S, Otto C, et al. Induction of dermalepidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005 Apr; 115 (4): 870-878
20. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005 Dec; 14 (12): 861-875
21. Lazarova Z, Yee C, Darling T, et al. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996 Oct 1; 98 (7): 1509-1518
22. Wolverton SE. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001
23. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001
24. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 1986; 122: 670-674
25. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70: 51-55
26. Humbert P, Treffel P, Chapuis JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691-697
27. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.NEngl JMed 2001 Sep 6; 345 (10): 747-755
28. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005 Dec; 115 (12): 3440-3450
29. Sesarman A, Sitaru AG, Olaru F, et al. Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med 2008 Aug; 86 (8): 951-959
30. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?" Clin Immunol 2005 Dec; 117 (3): 207-213
31. Schmidt E, Hunzelmann N, Zillikens D, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006 Jul; 31 (4): 503-508
32. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-496
33. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004 Aug; 4 (4): 398-402
34. Zillikens D, Derfler K, Eming R, et al. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007; 5: 881-887
35. Rook A, Wilkinson DS, Ebling FJG. Textbook of dermatology. Oxford: Blackwell Scientific Publications, 1979
36. Bean SF. Bullous pemphigoid. In: Ahmed AR, editor. Clinical dermatology. Philadelphia (PA): JB Lippincott, 1987: 13-17
37. Marsden RA, McKee PH, Bhogal B, et al. A study of benign chronic bullous dermatosis of childhood and comparison with dermatitis herpetiformis and bullous pemphigoid occurring in childhood. Clin Exp Dermatol 1980; 5: 159-172
38. Jordon RE. Bullous pemphigoid, cicatricial pemphigoid, and chronic bullous dermatosis of childhood. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill, Inc., 1987: 580-586
39. Sison-Fonacier L, Bystryn JC. Regional variations in antigenic properties of skin: a possible cause for diseasespecific distribution of skin lesions. J Exp Med 1986; 164: 2125-2130
40. Downham TF, Chapel TA. Bullous pemphigoid: therapy in patients without diabetes mellitus. Arch Dermatol 1978; 114: 1639-1642
41. Provost TT, Maize JC, Ahmed AR, et al. Unusual subepidermal bullous diseases with immunologic features of bullous pemphigoid. Arch Dermatol 1979; 115: 156-160
42. Ahmed AR, Newcomer VD. Bullous pemphigoid. In: Ahmed AR, editor. Clinical dermatology. Philadelphia (PA): JB Lippincott, 1987: 6-12
43. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113: 1043-1046
44. Bingham EA, Burrow D, Sanford JC. Prolonged pruritus and bullous pemphigoid. Clin Exp Dermatol 1984; 9: 564-570
45. Lever WF. Pemphigus and pemphigoid. Springfield (IL): Charles C. Thomas, 1965
46. Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987; 16: 907-924
47. Person JR, Rogers III RS. Bullous and cicatricial pemphigoid: clinical, histopathologic and immunopathologic correlations. Mayo Clin Proc 1977; 52: 54-66
48. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008 Oct; 59 (4): 582-588
49. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study [abstract]. BMJ 2008; 337: a180
50. Savin JA. Bullous pemphigoid. In: Ahmed AR, editor. Clinical dermatology. Philadelphia (PA): JB Lippincott, 1987: 52-59
51. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol 2002; 138: 903-908
52. Joly P, Roujeau J-C, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-327 (Pubitemid 34438839)
53. Flotte TJ. Pathology of pemphigoid. Clin Dermatol 1987; 5: 71-80
54. Lever WF, Schaumburg-Lever G. Histopathology of the skin. 6th ed. Philadelphia (PA): JB Lippincott Co., 1983
55. Mutasim DF, Diaz LA. The relevance of immunohistochemical techniques in the differentiation of subepidermal bullous diseases. Am J Dermatopathol 1991; 13: 77-83
56. Church R. Pemphigoid treated with corticosteroids. Br J Dermatol 1960; 72: 431-441
57. Siegel J, Eaglstein WH. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984; 120: 1157-1165
58. Greaves MW, Burton JL, Marks J, et al. Azathioprine in the treatment of bullous pemphigoid. BMJ 1971; 1: 144-145
59. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid: a 4 year follow-up. Br J Dermatol 1974; 91: 103-109
60. Ahmed AR, Moy R. Azathioprine. Int J Dermatol 1981; 20: 461-469
61. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1972; 106: 657-661
62. Ahmed AR, Hombal SM. Cyclophosphamide (cytoxan): a review of relevant pharmacology and clinical use. J Am Acad Dermatol 1984; 6: 1115-1126
63. Thivolet J, Barthelemy H, Rigot-Muller G, et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1: 334-335
64. Person JR, Rogers III RS. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977; 113: 610-615
65. Goldberg NS, Robinson JK, Roenigk Jr HH, et al. Plasmapheresis therapy for bullous pemphigoid. Arch Dermatol 1985; 121: 1484-1485
66. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 2: 486-489
67. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53
68. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 2001; 44: 83-88
69. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional treatment. J Am Acad Dermatol 2001; 45: 679-690
70. Thomas I, Khorenian S, Arbesteld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28: 74-77
71. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-758
72. Khumalo N, Kirtschig G, Middleton P, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2005 Jul 20; (3): CD002292
73. Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-221
74. Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007 Feb; 156 (2): 352-356
75. Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008 Feb; 34 (1): 56-64
76. Jacoby Jr WD, Bartholome CW, Ramchand SC, et al. Cicatricial pemphigoid (Brunsting-Perry type) case report and immunofluorescence findings. Arch Dermatol 1978; 114: 779-781
77. Michel B, Bean SF, Chorzelski T, et al. Cicatricial pemphigoid of Brunsting-Perry: immunofluorescent studies. Arch Dermatol 1977; 113: 1403-1405
78. Brunsting LA, Perry HO. Benign pemphigoid: a report of seven cases with chronic, scarring, herpetiform plaques about the head and neck. Arch Dermatol 1957; 75: 489-501
79. Fine J-D. Cicatricial pemphigoid. In: Wojnarowska F, Briggaman RA, editors. Management of blistering diseases. New York: Raven Press, 1990: 83-92
80. Fine J-D. Cicatricial and localized pemphigoid. In: Jordon RE, editor. Immunologic diseases of the skin. Norwalk (CT): Appleton and Lange, 1991: 303-313
81. Laskaris G, Sklavounou A, Stratigos J. Bullous pemphigoid, cicatricial pemphigoid and pemphigus vulgaris: a comparative clinical survey of 278 cases. Oral Surg Oral Med Oral Pathol 1982; 54: 656-662
82. Foster ME, Nally FF. Benign mucous membrane pemphigoid (cicatricial mucosal pemphigoid): a reconsideration. Oral Surg Oral Med Oral Pathol 1977; 44: 697-705
83. Leonard JN, Wright P, Williams DM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol 1984; 110: 307-314
84. Frith PA, Venning VA, Wojnarowska F, et al. Conjunctival involvement in cicatricial and bullous pemphigoid: a clinical and immunopathological study. Br J Ophthalmol 1989; 73: 52-56
85. Venning VA, Frith PA, Bron AJ, et al. Mucosal involvement in bullous and cicatricial pemphigoid: a clinical and immunopathological study. Br J Dermatol 1988; 118: 7-15
86. Behlen CH, Mackey DM. Benign mucous membrane pemphigus with a generalized eruption. Arch Dermatol 1965; 92: 566-567
87. Ackerman AB. Histologic diagnosis of inflammatory skin diseases. Philadelphia (PA): Lea and Febiger, 1978
88. Lever WF, Schaumburg-Lever G. Non-infectious vesicular and bullous diseases. In: Lever WF, Schaumburg-Lever G, editors. Histopathology of the skin. 7th ed. Philadelphia (PA): JB Lippincott Co., 1990: 103-151
89. Brauner GJ, Jimbow K. Benign mucous membrane pemphigoid: an unusual case with electron microscopic findings. Arch Dermatol 1972; 106: 535-540
90. Fine J-D, Neises GR, Katz SI. Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. J Invest Dermatol 1984; 82: 39-43
91. Bean SF, Waisman M, Michel B, et al. Cicatricial pemphigoid: immunofluorescent studies. Arch Dermatol 1972; 106: 195-199
92. Fleming MG, Valenzuela R, Bergfeld WF, et al. Mucous gland basement membrane immunofluorescence in cicatricial pemphigoid. Arch Dermatol 1988; 124: 1407-1410
93. Anhalt GJ, Morrison LH. Bullous and cicatricial pemphigoid. Autoimmunity 1991; 4: 17-35
94. Thorne JE, Woreta FA, Jabs DA, et al. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008; 115: 2146-2152
95. Rogers III RS, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6: 215-223
96. Rogers III RS, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7: 201-205
97. Fern AI, Jay JL, Young H, et al. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol 1992; 76: 332-335
98. Elder MJ, Leonard J, Dart JK. Sulphapyridine: a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80: 549-552
99. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998; 23: 254-257
100. Dragan L, Eng AM, Lam S, et al. Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid. Cutis 1999; 63: 181-183
101. Poskitt L, Wojnarowska F. Minimizing cicatricial pemphigoid orodynia with minocycline. Br J Dermatol 1995; 132: 784-789
102. Brody HJ, Pirozzi DJ. Benign mucous membrane pemphigoid: response to therapy with cyclophosphamide. Arch Dermatol 1977; 113: 1598-1599
103. Dave VK, Vickers CFH. Azathioprine in the treatment of mucocutaneous pemphigoid. Br J Dermatol 1974; 90: 183-186
104. Kirtschig G, Murrell D, Wojnarowska F, et al. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; (1): CD004056
105. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. Ophthalmology 1999; 106: 2136-2143
106. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid. Arch Dermatol 2001; 137: 1181-1189
107. Sami N, Bhol KC, Ahmed AR. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol Immunopathol 2002; 102: 59-67
108. Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human a6 integrin. Clin Exp Immunol 2002; 129: 533-540
109. Mackay IR, Rosen FS. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755
110. Letko E, Bhol K, Foster CS, et al. Influence of intravenous immunoglobulin therapy on serum levels of anti-b4 antibodies in ocular cicatricial pemphigoid. Curr Eye Res 2000; 21: 646-654
111. Taverna JA, Lerner A, Bhawan J, et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007 Jul; 6 (7): 731-732
112. Meyer-ter-Vehn T, Schmidt E, Zillikens D, et al. Mucous membrane pemphigoid with ocular involvement. Part II: therapy. Ophthalmologe 2008 Apr; 105 (4): 405-419
113. Yaoita H, Briggaman RA, Lawley TJ, et al. Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol 1981; 76: 288-292
114. Nieboer C, Boorsma DM, Woerdeman MJ, et al. Epidermolysis bullosa acquisita: immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol 1980; 102: 383-392
115. Woodley DT, Briggaman RA, O'Keefe EJ, et al. Identification of the skin basement membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310: 1007-1013
116. Sakai LY, Keene DR, Morris NP, et al. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 1986; 103: 1577-1586
117. Briggaman RA, Wheeler Jr CE. The epidermal-dermal junction. J Invest Dermatol 1975; 65: 71-84
118. Vodegel RM, de Jong MC, Pas HH, et al. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol 2002 Dec; 47 (6): 919-925
119. Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001; 44: 818-828
120. Cunningham BB, Kirchmann TTT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34: 781-784
121. Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita: successful treatment with colchicine. Arch Dermatol Res 1994; 286: 35-40
122. Kofler H, Wambacher-Gasser B, Topar G, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34: 331-335
123. Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997; 136: 415-420
124. Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Lowdose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741-748
125. Schmidt E, Benoit S, Brocker EB, et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006 Feb; 142 (2): 147-150
126. Ansel J, Petrozzi JW, Kumar V. Possible drug-induced pemphigus-like antibodies with clinical manifestation of erythema multiforme. Arch Dermatol 1983; 119: 1006-1009
127. Coulson IH, Cook MG, Bruton J, et al. Atypical pemphigus vulgaris associated with angio-follicular lymph node hyperplasia (Castleman's disease). Clin Exp Dermatol 1986; 11: 656-663
128. Gili A, Ngan BY, Lester R. Castleman's disease associated with pemphigus vulgaris. J Am Acad Dermatol 1992; 25: 955-959
129. Tagami S, Imamura S, Noguchi S, et al. Co-existence of peculiar pemphigus, myasthenia gravis and malignant thymoma. Dermatologica 1976; 152: 181-190
130. Anhalt GJ, Kim S, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-1735
131. Fullerton SH, Woodley DT, Smoller BR, et al. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA 1992; 267: 1500-1502
132. Lam S, Stone MS, Goeken JA, et al. Paraneoplastic pemphigus, cicatricial conjunctivitis, and acanthosis nigricans with pachydermatoglyphy in a patient with bronchogenic squamous cell carcinoma. Ophthalmology 1992; 99 (1): 108-113
133. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 12: 77-96; discussion 97
134. Camisa C, Helm TN, Liu YC, et al. Paraneoplastic pemphigus: a report of three cases including one long-term survivor. J Am Acad Dermatol 1992 Oct; 27 (4): 547-553
135. Hertzberg MS, Schifter M, Sullivan J, et al. Paraneoplastic pemphigus in two patients with B cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63: 105-106
136. Williams JV, Marks Jr JG, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506-508
137. Dega H, LaPorte JL, Joly P, et al. Paraneoplastic pemphigus associated with Hodgkin's disease. Br J Dermatol 1998; 138: 196-197
138. Robinson ND, Hashimoto T, Amagai M, et al. The new pemphigus variants. J Am Acad Dermatol 1999; 40: 649-671
139. Korman NJ. New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 2000; 18: 127-137
140. Krunic ALJ, Kokai D, Bacetic B, et al. Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption. Int J Dermatol 1997; 36: 526-529